Much like the recent addition of heart disease as a condition these GLP-1s can treat, research is informing additional conditions for which these drugs are indicated
Discussing this with biotech/pharma sponsors and building some dose escalation buffer into a protocol to keep the participant in the study and manage these AEs (when possible) can be a good strategy to keep participants in the trial & improve their experience
GLP-1 receptor agonists, such as Semaglutide, are FDA-approved prescription medications that play a crucial role in regulating food intake, controlling blood sugar levels, and enhancing feelings of fullness
The interactions of oxyntomodulin differed, with more transient contacts deep within the peptide binding cavity and with residues along the peptide exposed face of TM2, ECL1 and ECL2
Responsible eating involves making thoughtful food choices that support a nutrient-dense diet
It gives clean numbers for standard 200-300mcg doses